Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933865 · ClinicalTrials.gov registry record · Phase 1
Acute Pain Management in Patients on Opioid Replacement Therapy
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03933865 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 1 participants.
The verdict
NCT03933865, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an outpatient randomized within subject placebo-controlled human laboratory investigation of analgesia (as assessed with quantitative sensory testing; QST) from ketamine alone and in combination with hydromorphone in buprenorphine maintained participants. The goals of this project are to characterize the analgesic, subjective, and physiologic effects of ketamine combined with hydromorphone in patients on buprenorphine maintenance for opioid use disorder.
Interventions
- DRUG Ketamine
- DRUG Placebos
- DRUG HYDROmorphone Injectable Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2022-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03933865
The ClinicalTrials.gov registry entry for NCT03933865 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT03933865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03933865 about?
NCT03933865 is a clinical study titled "Acute Pain Management in Patients on Opioid Replacement Therapy". This is an outpatient randomized within subject placebo-controlled human laboratory investigation of analgesia (as assessed with quantitative sensory testing; QST) from ketamine alone and in combination with hydromorphone in buprenorphine maintained participants. The goals of this project are to cha...
What is the current status of trial NCT03933865?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2018-10-31. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT03933865?
The interventions under investigation include: Ketamine (DRUG), Placebos (DRUG), HYDROmorphone Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT03933865?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.